SMAD4 deletion
|
Pancreatic Adenocarcinoma
|
SMAD4 deletion
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials
|
gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials
|
SMAD4 deletion
|
SCCHN
|
SMAD4 deletion
|
SCCHN
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
SMAD4 deletion
|
Head and Neck Cancer
|
SMAD4 deletion
|
Head and Neck Cancer
|
cisplatin Sensitive: D – Preclinical
|
cisplatin Sensitive: D – Preclinical
|